Integras Partners LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 31,045 shares of the biopharmaceutical company’s stock, valued at approximately $2,868,000. Gilead Sciences makes up 2.4% of Integras Partners LLC’s holdings, making the stock its 11th largest holding.
A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Swedbank AB boosted its holdings in shares of Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 60.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,493 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 565 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Gilead Sciences by 49.9% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 8,447 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 2,813 shares in the last quarter. Aptus Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 3.9% during the 3rd quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 309 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 0.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock worth $15,441,000 after buying an additional 948 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 311,285 shares of company stock valued at $31,284,910. 0.16% of the stock is owned by insiders.
Analyst Ratings Changes
View Our Latest Analysis on GILD
Gilead Sciences Trading Down 0.6 %
Shares of Gilead Sciences stock opened at $113.35 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm has a market cap of $141.16 billion, a PE ratio of 306.35, a P/E/G ratio of 0.71 and a beta of 0.21. The stock has a fifty day moving average price of $101.42 and a 200-day moving average price of $92.47. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.79%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- 3 Warren Buffett Stocks to Buy Now
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Golden Cross Stocks: Pattern, Examples and Charts
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- 5 Top Rated Dividend Stocks to Consider
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.